Blog

Home » Blog

Biolyse Pharma stymied in effort to make cheaper version of pricey prostate cancer drug

Hormone Therapy / By / / 1 minute of reading

A small Canadian company has waded into a U.S. drug price controversy by offering to make an expensive prostate cancer drug for a fraction of the price. Right now Xtandi costs U.S. patients as much as $129,000 US a year, or about $90 per pill. St. Catharines, Ont.-based Biolyse Pharma says it can make the drug for $3 a pill, or $4,400 per year, but has so far been unable to get U.S. health authorities to override the existing patent. Read the article here.

Biolyse Pharma stymied in effort to make cheaper version of pricey prostate cancer drug Read More »

Prostate Cancer Treatment Breakthrough

Chemotherapy / By / / 1 minute of reading

Scientists with Deakin’s School of Medicine have found that, when coupled with the milk protein lactoferrin, the chemotherapy drug Doxorubicin (Dox) can be delivered directly into the nucleus of prostate cancer cells and will kill them cells as well as drug resistant cancer stem cells, without any side-effects. Read the article here.

Prostate Cancer Treatment Breakthrough Read More »

What It’s Like to Be Part of a Prostate Cancer Support Group

General / By / / 1 minute of reading

Read this article for a perspective on what it’s like to be part of a support group like PCCN-Toronto, including: What role does a support group play in helping those diagnosed with prostate cancer?  Who attends support group meetings? Is there anything that wives, significant others, partners, or loved ones should know? There are also comments on this page from others.

What It’s Like to Be Part of a Prostate Cancer Support Group Read More »

Video: “The Future of PSA Based Prostate Cancer (PCa) Screening – Screening Smarter and Individualized Risk Assessment”

Videos, Awareness Nights, PSA Screening, Diagnosis / By / / 1 minute of reading

January 2017 Awareness Night The Future of PSA Based Prostate Cancer (PCa) Screening – Screening Smarter and Individualized Risk Assessment Dr. Raj Satkunasivam, MD, MS, FRCSC Urologic Oncologist,  Odette Cancer Centre, Sunnybrook Health Sciences Centre Assistant Professor, Division of Urology, Department of Surgery, University of Toronto     CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 40:51 minutes

Video: “The Future of PSA Based Prostate Cancer (PCa) Screening – Screening Smarter and Individualized Risk Assessment” Read More »

Psychological Effects From ADT a Growing Challenge in Prostate Cancer

Side Effects, Hormone Therapy / By / / 1 minute of reading

Androgen-deprivation therapy (ADT) can be associated with significant psychological effects in patients with prostate cancer. Additionally, these side effects—which include depression, Alzheimer disease, and coronary disease—are often under-reported by patients. Read the article here.

Psychological Effects From ADT a Growing Challenge in Prostate Cancer Read More »

Scroll to Top